New hope for lymphoma patients: tailored treatment shows promise

NCT ID NCT06793189

First seen Apr 08, 2026 · Last updated May 07, 2026 · Updated 3 times

Summary

This study tests a personalized treatment approach for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. Researchers will assign treatments based on each patient's risk level, aiming to improve cancer control and reduce side effects. About 145 adults will participate, and the main goal is to see how long the cancer stays away after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, China

    Contact Email: •••••@•••••

  • Peking University Third Hospital

    RECRUITING

    Beijing, China

    Contact Email: •••••@•••••

  • Shanghai Ruijin Hospital

    RECRUITING

    Shanghai, China, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.